BioMarin Q2 Revenue Jumps 20% to $990M, Raises Full-Year Outlook on Voxzogo Strength
BMRN sits 29% above its 52-week low of $49.259.
Summary
BioMarin delivered a strong Q2 with total revenues up 20% year-over-year to $990 million, driven by global demand for Voxzogo. Management raised full-year 2026 guidance for total revenues, Voxzogo (now expected to reach at least $1 billion), and non-GAAP diluted EPS. The company also submitted an sNDA for Voxzogo in hypochondroplasia following positive Phase 3 data, and the FDA accepted its sNDA for full approval in achondroplasia with a PDUFA date of February 28, 2027. Integration of the Amicus acquisition is progressing, with cost synergies expected to accelerate revenue growth and margin expansion. The pipeline advanced with new data for BMN 333 and the addition of BMN 820 for FSGS. This follows the May Phase 3 readout for Voxzogo in hypochondroplasia and the July 8-K/A detailing the Amicus acquisition financials. The raised guidance and multiple regulatory catalysts position the company for sustained growth.
At the time of this announcement, BMRN was trading at $63.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $49.26 to $66.28. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.